Novan is a pharmaceutical company focused on dermatology and anti-infective therapies. Co. has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. Co. has also introduced a possible anti-viral product candidate for the treatment of external genital warts (SB207). Co. has conducted or is conducting preclinical work on new chemical entities, including berdazimer sodium, and formulations for the potential treatment of SARS-CoV-2, the virus that causes COVID-19 (SB019); and antimicrobial indications for the adjacent companion animal health market (NVN4100).
NOVN — Key Stats (updated Friday, December 2, 10:36 AM)